Cangkrama Michael, Liu Huan, Wu Xiaoyu, Yates Josephine, Whipman James, Gäbelein Christoph G, Matsushita Mai, Ferrarese Luca, Sander Sibilla, Castro-Giner Francesc, Asawa Simran, Sznurkowska Magdalena K, Kopf Manfred, Dengjel Jörn, Boeva Valentina, Aceto Nicola, Vorholt Julia A, Werner Sabine
Institute of Molecular Health Sciences, Department of Biology, ETH Zurich, Zurich, Switzerland.
Department of Computer Science, ETH Zurich, Zurich, Switzerland.
Nat Cancer. 2025 Aug 28. doi: 10.1038/s43018-025-01038-6.
Cancer-associated fibroblasts (CAFs) are key components of the tumor microenvironment that commonly support cancer development and progression. Here we show that different cancer cells transfer mitochondria to fibroblasts in cocultures and xenograft tumors, thereby inducing protumorigenic CAF features. Transplantation of functional mitochondria from cancer cells induces metabolic alterations in fibroblasts, expression of CAF markers and release of a protumorigenic secretome and matrisome. These features promote tumor formation in preclinical mouse models. Mechanistically, the mitochondrial transfer requires the mitochondrial trafficking protein MIRO2. Its depletion in cancer cells suppresses mitochondrial transfer and inhibits CAF differentiation and tumor growth. The clinical relevance of these findings is reflected by the overexpression of MIRO2 in tumor cells at the leading edge of epithelial skin cancers. These results identify mitochondrial transfer from cancer cells to fibroblasts as a driver of tumorigenesis and provide a rationale for targeting MIRO2 and mitochondrial transfer in different malignancies.
癌症相关成纤维细胞(CAFs)是肿瘤微环境的关键组成部分,通常支持癌症的发展和进展。在此我们表明,在共培养和异种移植肿瘤中,不同的癌细胞会将线粒体转移至成纤维细胞,从而诱导促肿瘤的CAF特征。来自癌细胞的功能性线粒体移植会诱导成纤维细胞发生代谢改变、CAF标志物表达以及促肿瘤分泌组和基质组的释放。这些特征在临床前小鼠模型中促进肿瘤形成。从机制上来说,线粒体转移需要线粒体运输蛋白MIRO2。其在癌细胞中的缺失会抑制线粒体转移,并抑制CAF分化和肿瘤生长。这些发现的临床相关性体现在皮肤上皮癌前沿肿瘤细胞中MIRO2的过表达。这些结果确定了从癌细胞到成纤维细胞的线粒体转移是肿瘤发生的驱动因素,并为在不同恶性肿瘤中靶向MIRO2和线粒体转移提供了理论依据。
Cell Commun Signal. 2025-5-22
Cancer Cell. 2025-5-12
Nature. 2023-11
J Cell Biol. 2023-3-6